```
 e bepotastine/cn
E1            1     BEPOLIT D, POLYMER WITH 2,5-FURANDIONE AND 2,2'-OXYBIS(ETHAN
                    OL)/CN
E2            1     BEPOLIT D, POLYMER WITH 2,5-FURANDIONE, 1,2-PROPANEDIOL AND
                    1,2,3-PROPANETRIOL/CN
E3            1 --> BEPOTASTINE/CN
E4            1     BEPOTASTINE BENZENESULFONATE SALT/CN
E5            1     BEPOTASTINE BESILATE/CN
E6            1     BEPOTASTINE BESYLATE/CN
E7            1     BEPOTASTINE CALCIUM SALT/CN
E8            1     BEPOTASTINE L-MENTHYL ESTER/CN
E9            1     BEPOTASTINE L-MENTHYL ESTER N-BENZYLOXYCARBONYL-L-ASPARTATE
                    SALT/CN
E10           1     BEPOX 1073/CN
E11           1     BEPOX 10TS/CN
E12           1     BEPOX 1268/CN

=> s e3-e7
              1 BEPOTASTINE/CN
              1 "BEPOTASTINE BENZENESULFONATE SALT"/CN
              1 "BEPOTASTINE BESILATE"/CN
              1 "BEPOTASTINE BESYLATE"/CN
              1 "BEPOTASTINE CALCIUM SALT"/CN
L1            3 (BEPOTASTINE/CN OR "BEPOTASTINE BENZENESULFONATE SALT"/CN OR
                "BEPOTASTINE BESILATE"/CN OR "BEPOTASTINE BESYLATE"/CN OR "BEPOT
                ASTINE CALCIUM SALT"/CN)

=> file caplus
=> s l1
L2           66 L1

=> s liquid or aqueous
         912547 LIQUID
         160474 LIQUIDS
        1031002 LIQUID
                  (LIQUID OR LIQUIDS)
        1286005 LIQ
         120465 LIQS
        1331458 LIQ
                  (LIQ OR LIQS)
        1828095 LIQUID
                  (LIQUID OR LIQ)
         217955 AQUEOUS
              1 AQUEOUSES
         217956 AQUEOUS
                  (AQUEOUS OR AQUEOUSES)
        1186974 AQ
            222 AQS
        1187114 AQ
                  (AQ OR AQS)
        1241723 AQUEOUS
                  (AQUEOUS OR AQ)
L3      2927927 LIQUID OR AQUEOUS

=> s l2 and l3
L4            7 L2 AND L3

=> d ibib abs hitind 1-7
```

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:259702 CAPLUS <<LOGINID::20100402>>
DOCUMENT NUMBER: 146:302320
TITLE: Antihistamine- and corticosteroid-containing liposomes and compositions for treating rhinitis and related disorders
INVENTOR(S): Pereswetoff-Morath, Lena; Carlsson, Anders; Bjerke, Torbjoem
PATENT ASSIGNEE(S): Biolipox AB, Swed.
SOURCE: PCT Int. Appl., 38pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007026151	A1	20070308	WO 2006-GB3222	20060831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2616515	A1	20070308	CA 2006-2616515	20060831
EP 1919450	A1	20080514	EP 2006-779244	20060831
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009507009	T	20090219	JP 2008-528575	20060831
IN 2008DN00881	A	20080627	IN 2008-DN881	20080131
CN 101257891	A	20080903	CN 2006-80032191	20080303
US 20090324699	A1	20091231	US 2009-991091	20090410
PRIORITY APPLN. INFO.:			US 2005-712822P P	20050901
			WO 2006-GB3222 W	20060831

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1312374 CAPLUS <<LOGINID::20100402>>
DOCUMENT NUMBER: 146:68699
TITLE: Method and composition comprising polar lipid liposomes for treating inflammatory disorders
INVENTOR(S): Pereswetoff-Morath, Lena; Carlsson, Anders
PATENT ASSIGNEE(S): Biolipox AB, Swed.
SOURCE: PCT Int. Appl., 83pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2006131737	A2	20061214	WO 2006-GB2090		20060608
WO 2006131737	A3	20070329			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2006256518	A1	20061214	AU 2006-256518		20060608
CA 2608631	A1	20061214	CA 2006-2608631		20060608
EP 1888033	A2	20080220	EP 2006-744143		20060608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, MK, YU					
JP 2008542438	T	20081127	JP 2008-515287		20060608
NO 2007005660	A	20080222	NO 2007-5660		20071107
IN 2007DN08751	A	20071214	IN 2007-DN8751		20071114
KR 2008016621	A	20080221	KR 2007-728659		20071207
MX 2007015577	A	20080225	MX 2007-15577		20071207
CN 101193622	A	20080604	CN 2006-80020535		20071210
US 20090220583	A1	20090903	US 2009-921850		20090410
PRIORITY APPLN. INFO.:			US 2005-688698P	P	20050609
			US 2005-696777P	P	20050707
			WO 2006-GB2090	W	20060608

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 146:68699

AB Homogeneous pharmaceutical compns. for the treatment of inflammatory disorders are provided, comprising an anti-inflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically acceptable aqueous carrier. Thus, an injection solution was prepared containing fluticasone propionate 0.5 mg, soybean (Lipoid S100) 17.5 mg, DMPC 17.5 mg, benzalkonium chloride 0.1 mg, butylated hydroxytoluene 0.1 mg, citric acid 19.2 mg, sodium hydroxide 8.4 mg, 1M HCl and/or 1M NaOH to pH 5.5, and water for injection to 1 mL.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:179236 CAPLUS <<LOGINID::20100402>>
DOCUMENT NUMBER: 142:266777
TITLE: Pharmaceutical compositions containing epinastine and other anti-H1-histamines for treatment of skin disease
INVENTOR(S): Matsumoto, Ikki; Okada, Minoru; Umehara, Norimitsu
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 2005053907	A	20050303	JP 2004-223680		20040730
PRIORITY APPLN. INFO.:			EP 2003-16681	A	20030801

AB The invention relates to a pharmaceutical compns. for treatment of skin disease, e.g. urticaria, eczema, dermatitis, pruritus, psoriasis vulgaris, wherein the composition is characterized by containing epinastine and other anti-H1-histamine. A tablet containing epinastine hydrochloride and d-chlorpheniramine maleate with other ingredients was formulated.

IC ICM A61K031-55
ICS A61K031-131; A61K031-135; A61K031-137; A61K031-40; A61K031-437; A61K031-4402; A61K031-4418; A61K031-4436; A61K031-445; A61K031-4465; A61K031-495; A61K031-496; A61K031-5415; A61K031-542; A61K031-551; A61K045-00; A61P017-00; A61P017-04; A61P029-00

CC 63-6 (Pharmaceuticals)

IT Drug delivery systems
(liqs., oral; pharmaceutical compns. containing epinastine and other anti-H1-histamines for treatment of skin disease)

IT 58-73-1, Diphenhydramine 60-87-7, Promethazine 68-88-2, Hydroxyzine 84-96-8, Alimemazine 91-81-6, Tripelenamine 91-85-0 113-92-8 129-03-3, Cyproheptadine 132-18-3, Diphenylpyraline hydrochloride 147-20-6, Diphenylpyraline 482-15-5, Isothipendyl 486-12-4, Triprolidine 486-16-8, Carbinoxamine 522-24-7, Phenetazine 524-81-2, Mebhydrolin 848-53-3, Homochlorcyclizine 1982-37-2, Methdilazine 2438-32-6, d-Chlorpheniramine maleate 7491-10-3, Diphenhydramine salicylate 13946-02-6, Iproheptine 14587-50-9, Dipheterol 15686-51-8, Clemastine 29216-28-2, Mequitazine 34580-13-7, Ketotifen 50679-08-8, Terfenadine 58581-89-8, Azelastine 60607-34-3, Oxatomide 80012-43-7, Epinastine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 87233-61-2, Emedastine 90729-43-4, Ebastine 103659-13-8 108929-04-0, Epinastine hydrochloride 113806-05-6, Olopatadine 125602-71-3 , Bepotastine 845964-02-5 845964-03-6 845964-04-7 845964-05-8 845964-06-9 845964-07-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing epinastine and other anti-H1-histamines for treatment of skin disease)

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:203679 CAPLUS <<LOGINID::20100402>>
DOCUMENT NUMBER: 140:229437
TITLE: The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis and/or allergic conjunctivitis
INVENTOR(S): Marx, Degenhard; Muller, Helgert
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019955	A1	20040311	WO 2003-EP9622	20030829
W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2495830	A1	20040311	CA 2003-2495830	20030829
AU 2003273396	A1	20040319	AU 2003-273396	20030829

AU 2003273396	B2	20081211			
BR 2003013611	A	20050621	BR 2003-13611		20030829
EP 1545548	A1	20050629	EP 2003-755551		20030829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1674916	A	20050928	CN 2003-819860		20030829
JP 2005539044	T	20051222	JP 2004-532150		20030829
NZ 538954	A	20070427	NZ 2003-538954		20030829
ZA 2005000719	A	20060222	ZA 2005-719		20050125
IN 2005MN00097	A	20051104	IN 2005-MN97		20050131
MX 2005001885	A	20050603	MX 2005-1885		20050216
US 20050245493	A1	20051103	US 2005-524821		20050218
NO 2005001521	A	20050322	NO 2005-1521		20050322
PRIORITY APPLN. INFO.:			EP 2002-19406	A	20020830
			WO 2003-EP9622	W	20030829

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to a combination of ciclesonide with an antihistamine (e.g. azelastine) for the treatment of allergic rhinitis and/or allergic conjunctivitis.

IC ICM A61K031-58
ICS A61P037-08; A61P011-00

CC 1-7 (Pharmacology)

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:100995 CAPLUS <<LOGINID::20100402>>
DOCUMENT NUMBER: 140:117446
TITLE: Aqueous liquid preparations and light-stabilized aqueous liquid preparations of bepotastine
INVENTOR(S): Higashiyama, Masayo
PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011001	A1	20040205	WO 2003-JP9713	20030730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003252746	A1	20040216	AU 2003-252746	20030730
JP 3631748	B2	20050323	JP 2004-524320	20030730
EP 1525884	A1	20050427	EP 2003-771445	20030730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1612734	A	20050504	CN 2003-801903	20030730
CN 1293880	C	20070110		
US 20050107429	A1	20050519	US 2004-500354	20040630

PRIORITY APPLN. INFO.: JP 2002-223804 A 20020731
WO 2003-JP9713 W 20030730
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Disclosed are aqueous liquid prepns. containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or pharmacol. acceptable acid-addition salts thereof, which are stabilized with water-soluble metal chlorides. An eye drop solution contained bepotastine besilate 0.3, $NaH_2PO_4 \cdot 2H_2O$ 0.1, NaCl 0.79, benzalkonium chloride 0.005 g, NaOH q.s. to pH 6.8, and distilled water to 100 mL.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:900754 CAPLUS <<LOGINID::20100402>>
DOCUMENT NUMBER: 137:346182
TITLE: Drug preparations for cold and rhinitis
INVENTOR(S): Okudaira, Ichio; Ichihara, Takashi; Nakagami, Joji; Aikawa, Katsuyoshi; Nakagawa, Yasuo
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002338486	A	20021127	JP 2001-144658	20010515

PRIORITY APPLN. INFO.: JP 2001-144658 20010515
AB Drug prepns. containing (A) antiallergics, including emedastine, ebastine, lamatroban, and/or bepotastine and their salts, (b) parasympatholytics, including belladonna total alkaloid, belladonna extract, scopolia extract, isopropamide iodide, and/or datura extract are claimed for treatment of cold and rhinitis and reduction of nasal secretion. Formulation examples of tablets and liqs. were given.
IC ICM A61K035-78
ICS A61K031-16; A61K031-403; A61K031-445; A61K031-551; A61P027-16; A61P031-16
CC 1-7 (Pharmacology)
Section cross-reference(s): 63
IT Drug delivery systems
(liqs.; antiallergic and parasympatholytic drug prepns. for cold and rhinitis)
IT 71-81-8, Isopropamide iodide 91-81-6, Tripelennamine 147-24-0, Diphenhydramine hydrochloride 87233-61-2, Emedastine 90729-43-4, Ebastine 116649-85-5, Ramatroban 125602-71-3, Bepotastine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiallergic and parasympatholytic drug prepns. for cold and rhinitis)

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:485054 CAPLUS <<LOGINID::20100402>>
DOCUMENT NUMBER: 129:122577
ORIGINAL REFERENCE NO.: 129:25117a,25120a
TITLE: Acid-addition salts of optically active piperidine compound and process for producing the same
INVENTOR(S): Kita, Jun-ichiro; Fujiwara, Hiroshi; Takamura, Shinji; Yoshioka, Ryuzo; Ozaki, Yauhiko; Yamada, Shin-ichi
PATENT ASSIGNEE(S): Ube Industries, Ltd., Japan; Tanabe Seiyaku Co., Ltd.
SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9829409	A1	19980709	WO 1997-JP4826	19971225
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 2000159762	A	20000613	JP 1996-347851	19961226
JP 3157117	B2	20010416		
JP 2000159763	A	20000613	JP 1996-347853	19961226
JP 3157118	B2	20010416		
JP 10237070	A	19980908	JP 1997-350784	19971219
JP 3107784	B2	20001113		
JP 2000198784	A	20000718	JP 2000-32961	19971219
TW 486475	B	20020511	TW 1997-86119702	19971224
CA 2275987	A1	19980709	CA 1997-2275987	19971225
CA 2275987	C	20061219		
AU 9878906	A	19980731	AU 1998-78906	19971225
EP 949260	A1	19991013	EP 1997-949235	19971225
EP 949260	B1	20020522		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1242013	A	20000119	CN 1997-181039	19971225
CN 1098262	C	20030108		
AT 217872	T	20020615	AT 1997-949235	19971225
PT 949260	E	20020930	PT 1997-949235	19971225
ES 2173499	T3	20021016	ES 1997-949235	19971225
US 6307052	B1	20011023	US 1999-331792	19990625
HK 1022477	A1	20021004	HK 2000-101619	20000316
US 20020026054	A1	20020228	US 2001-949809	20010912
US 6780877	B2	20040824		
CN 1446812	A	20031008	CN 2002-127163	20020730
CN 1231478	C	20051214		
US 20040220226	A1	20041104	US 2004-771361	20040205
US 7282589	B2	20071016		
JP 2007145852	A	20070614	JP 2007-109	20070104

PRIORITY APPLN. INFO.:		
JP 1996-347851	A	19961226
JP 1996-347853	A	19961226
JP 1996-347895	A	19961226
JP 1997-350784	A3	19971219
JP 2000-32961	A3	19971219
WO 1997-JP4826	W	19971225
US 1999-331792	A3	19990625
US 2001-949809	A3	20010912

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
GI



I

AB Claimed are benzenesulfonate and benzoate of (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid of formula (I) (wherein * represents an asym. carbon atom) which are excellent in antihistaminic and antiallergic activities, and a process for producing them. Thus, optical resolution of (±)-4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine [(±)-II] with (2R,3R)-2-hydroxy-3-(4-methoxyphenyl)-3-(2-nitro-5-chlorophenylthio)propionic acid (III) by preferential crystallization of diastereomer salt (S)-(-)-II.III from H2O/EtOH (7/30 mL) gave (S)-4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine (100% ee) which was alkylated by Et 4-bromobutyrate in refluxing acetone containing K2CO3 for 7 h to give Et (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyrate (IV). The latter ester IV was stirred with a mixture of aqueous 5 N NaOH and EtOH at room temperature overnight followed by acidification with aqueous 5 N HCl to give I as a foam. I was converted into I.benzenesulfonic acid salt. I.benzenesulfonic acid salt and I.benzoic acid salt were nonhygroscopic and stable and not racemized when they were stored at 40° and 75% relative humidity for 1 mo, while the ester IV was increased in amount of the (R)-isomer under the same condition.

IC ICM C07D401-12
ICS A61K031-445; C07M007-00

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))

IT 125602-71-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(optical resolution; preparation of acid-addition salts of optically active piperidine as antihistaminic and antiallergic agents)

IT 125602-71-3P 190730-39-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of acid-addition salts of optically active piperidine as antihistaminic and antiallergic agents)

IT 190786-44-8P 210095-36-6P 210095-48-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acid-addition salts of optically active piperidine as antihistaminic and antiallergic agents)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT